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Colistin resistance involving Gram-negative bacilli infections is a challenge for health insti-
tutions around of the world. Carbapenem-resistance among these isolates makes colistin
the last therapeutic option for this treatment. Colistin resistance among Enterobacteriaceae,
Acinetobacter spp., and Pseudomonas spp. was evaluated between 2010 and 2014 years, at
Hospital das Clínicas, São Paulo, Brazil. Over ﬁve years 1346 (4.0%) colistin resistant Gram-
negative bacilli were evaluated. Enterobacteriaceae was the most frequent (86.1%) pathogen
isolated, followed by Acinetobacter spp. (7.6%), and Pseudomonas spp. (6.3%). By temporal anal-
ysis there was a trend for an increase of colistin resistance among Enterobacteriaceae, but
not  among non-fermentative isolates. Among 1346 colistin resistant isolates, carbapenem
susceptibility was observed in 21.5%. Colistin resistance in our hospital has been alarm-
ingly increased among Klebsiella pneumoniae isolates in both KPC positive and negative, thusarbapenem-resistant becoming a therapeutic problem.
©  2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
spp. (11.8%), and Pseudomonas spp. (10.1%). These pathogens
30
31he dissemination of infections caused by multi-drug resis-
ant Gram-negative isolates has become a major public heathPlease cite this article in press as: Rossi F, et al. Emergence of colistin resis
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hallenge worldwide. According to the last report of the Brazil-
an Health Surveillance Agency (ANVISA), Klebsiella pneumoniae
s the third pathogen isolated from patients admitted to
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 on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego,
exhibited elevated rates of resistance to carbapanems, mainly
among Acinetobacter spp. isolates (80.7%).1 In this circum-
stances, polymyxins are one of the last therapeutic options;
lsevier Editora Ltda. This is an open access article under the CC
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however, reports of resistance to colistin around the world are
increasing over time.2–4
The carbapenem resistance rates among Acinetobacter spp.
isolates in our institution, increased from 30% to 70%, between
2010 and 2014 (data not showed). Therefore, colistin became
the ﬁrst-line drug for Gram-negative infections in patients
admitted to ICU in the last ﬁve years. Few data on col-
istin resistance in Brazil are currently found in the literature.
Despite the good activity still displayed by polymyxins against
non-fermentative microorganisms, reduction in susceptibil-
ity rates has been observed among Enterobacteriaceae.5,6
In this study, colistin resistance among Enterobacteriaceae,
Acinetobacter spp., and Pseudomonas spp. clinical isolates was
retrospectively evaluated from the database of Microbiology
Laboratory of Hospital das Clínicas, São Paulo, Brazil, between
2010 and 2014. No surveillance or community-acquired iso-
lates were included in the analysis, and only one isolate for
each patient was evaluated in the study. The clinical samples
were received from nine hospitals of São Paulo city: Hospi-
tal das Clínicas – Instituto Central; Instituto do Câncer do
Estado de São Paulo – ICESP; Instituto do Corac¸ão – INCOR;
Instituto de Ortopedia e Trauma – IOT; Instituto de Psiquia-
tria – IPQ; Instituto de Radiologia – INRAD; Hospital do Cotoxó;
Instituto da Crianc¸a  – ICR, and Hospital de Suzano. The data
were analyzed using Excel and WHONET 5.6 softwares (World
Health Organization, http://www.whonet.org/www/software.
html).
The identiﬁcation of isolates and colistin susceptibility
test were performed by Vitek 2 (bioMérieux, France), and
the colistin-resistant MICs were conﬁrmed by Etest meth-
ods, according to CLSI recommendations.7 The Etest method
was previously validated on the microbiology laboratory using
broth microdilution (Trek Diagnostics Systems), according to
CLSI recommendations.7 The susceptibility categories were
interpreted according to break-points of CLSI guidelines8 for
non-fermentative isolates and EUCAST9 for Enterobacteriaceae
members.
Between 2010 and 2014, 33,765 Gram-negative bacilli from
non-repeated patients were tested for colistin resistance in
the microbiology laboratory. Enterobacteriacea species was the
most frequent group representing 49% (16,533 isolates) of
all Gram-negative tested, followed by Pseudomonas spp. and
Acinetobacter spp. (29% [9786 isolates] and 22% [7446 isolates],
respectively). Four percent (1346 isolates) of all Gram-negative
bacilli tested were resistant to colistin with MICs ranging from
2 to >32 mg/L. Among colistin-resistant isolates, Enterobacteri-
aceae were recovered most frequently from urine (34.8%), while
Acinetobacter spp. and Pseudomonas spp. were more  often iso-
lated from respiratory samples (45% and 35.3%, respectively).
Seven percent (1159 isolates) of Enterobacteriaceae isolates were
resistant to colistin, while 1.4% (102 isolates) of Acinetobacter
spp. and 0.9% (85 isolates) of Pseudomonas spp. showed and
colistin resistance over the ﬁve years evaluated in this study
(Table 1). Among Enterobacteriaceae members, K. pneumoniae
was the most frequent with 975 isolates (84.1%), followed by
Enterobacter cloacae (86 isolates, 7.4%), E. aerogenes (42 isolates,Please cite this article in press as: Rossi F, et al. Emergence of colistin resis
over ﬁve years. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016
3.6%), Escherichia coli (36 isolates, 3.1%), Citrobacter freundii (6
isolates, 0.5%), Salmonella spp. (5 isolates, 0.4%), Pantoea spp.
(4 isolates, 0.3%), K. ornithinolytica (3 isolates, 0.2%), and E.
asburiae (2 isolates, 0.1%) (Table 2). 6;x x x(x x):xxx–xxx
Since resistance to carbapenem in our institution is ele-
vated, in the last ﬁve years colistin became the ﬁrst-line drug
for treating infections caused by Gram-negative pathogens in
patients admitted to the ICUs of HC-FMUSP. Previous studies
indicate that the emergence of colistin-heteroresistant pop-
ulations may be ampliﬁed by colistin exposure.10,11 Data of
Sentry Surveillance Program show high susceptibility rates to
colistin worldwide until 2010 (Pseudomonas spp., 99.4%; Acine-
tobacter spp., 98.3%; and K. pneumoniae, 96.8%).3,12 The decrease
of susceptibility to colistin among these isolates is a ther-
apeutic challenge due to restricted therapeutic options. In
our study, a trend of increase in colistin resistance rate was
observed among Enterobacteriaceae family members, from 6.6%
(111 isolates) in 2010 to 9.4% (383 isolates) in 2014 (Table 1).
Since the ﬁrst description of KPC-2-producing K. pneumoniae
in Brazil, in 2009, studies have been published showing the
spread of this carbapanemase, including to other bacterial
species, in all regions.13–15 Over 80% of carbapenem-resistant
K. pneumoniae from our institution is KPC-producer (data not
showed). The spread of these phenotype and consequent
increased use of colistin, may have contributed to the rise of
colistin resistance rates observed in this study.
Fortunately, this trend was not observed among the non-
fermentative isolates Acinetobacter spp. and Pseudomonas spp.
In contrast, there was a slight reduction of colistin resistance
rates (1.5% [22 isolates] to 0.9% [16 isolates] and 1.5% [25 iso-
lates] to 0.5% [10 isolates], respectively), between 2010 and
2014 (Table 1). Previous Brazilian studies with carbapenem
resistant P. aeruginosa and A. baumannii showed high sus-
ceptibility rates to colistin.7,16,17 In contrast, K. pneumoniae
has demonstrated reduction of colistin susceptibility rates.18
Although resistance to colistin among Acinetobacter spp. in our
Institution turned out to be not as high as compared to K. pneu-
moniae, it still represents a serious problem in our hospital,
since carbapenem resistance among this species is elevated,
and colistin is the only available antibiotic for treating these
infections.
Furthermore, it should be pointed out that among colistin-
resistant isolates 21.5% were susceptible to carbapenem
(244 Enterobacteriaceae members [21.1%]; 23 Acinetobacter spp.
[22.5%], and 23 Pseudomonas spp. [27.1%]). This phenotype
is not frequently described, probably because many  clini-
cal laboratories only evaluate colistin susceptibility among
carbapenem-resistant isolates. This phenotype deserves spe-
cial attention because these isolates are also candidates to
acquire resistance to carbapenems, leaving no therapeutic
option for treating these infections. Olaitan et al.19 afﬁrm
that clinicians and microbiologists should be vigilant for the
possible existence of colistin-resistant bacteria not only in
patients undergoing colistin therapy, since such resistant bac-
teria could later be selected if colistin is used.
The main limitation of our study was the use of an auto-
mated method for determination of MIC to colistin. So, the
Etest method was used to conﬁrm the colistin MICs and reduce
the possibility of errors. In addition, the Etest method was pre-
viously validated, comparing with broth microdilution results,BJID 657 1–4
tance in the largest university hospital complex of São Paulo, Brazil,
.09.011
according to CLSI recommendations. In addition, different
brands of Mueller Hinton agar were evaluated during the Etest
validation to avoid the possibility of misinterpretation due to
inﬂuences of cations concentrations.20
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Table 1 – Susceptibility and resistance rates among Enterobacteriaceae, Acinetobacter spp., and Pseudomonas spp. isolated
to colistin between 2010 and 2014, in HC-FMUSP.
Year (no. tested) Colistin susceptibility proﬁle
MIC (mg/L) Percentage by category (no.)b
MIC50/MIC90 Rangea Susceptibility Resistance
Enterobacteriaceae
2010 (1682) 0.5/1.0 ≤0.5–>32 93.4 (1571) 6.6 (111)
2011 (3833) 0.5/0.5 ≤0.5–>32 95.8 (3672) 4.2 (161)
2012 (2724) 0.5/0.5 ≤0.5–>32 94.2 (2566) 5.8 (158)
2013 (4220) 0.5/0.5 ≤0.5–>32 91.8 (3874) 8.2 (346)
2014 (4074) 0.5/2.0 ≤0.5–>32 90.6 (3691) 9.4 (383)
All years (16533) 0.5/1 ≤0.5–>32 93.0 (15374) 7.0 (1159)
Acinetobacter spp.
2010 (N = 1467) 0.5/1.0 ≤0.5–>32 98.5 (1445) 1.5 (22)
2011 (N = 1111) 0.5/1.0 ≤0.5–4.0 97.3 (1081) 2.7 (30)
2012 (N = 1363) 0.5/0.5 ≤0.5–>32 98.9 (1348) 1.1 (15)
2013 (N = 1727) 0.5/0.5 ≤0.5–>32 98.9 (1708) 1.1 (19)
2014 (N = 1778) 0.5/0.5 ≤0.5–>32 99.1 (1762) 0.9 (16)
All years (7446) 0.5/1 ≤0.5–>32 98.6 (7344) 1.4 (102)
Pseudomonas spp.
2010 (N = 1667) 2.0/2.0 ≤0.5–>32 98.5 (1642) 1.5 (25)
2011 (N = 1769) 2.0/2.0 ≤0.5–>32 98.7 (1746) 1.3 (23)
2012 (N = 1600) 0.5/2.0 ≤0.5–>32 99.0 (1584) 1.0 (16)
2013 (N = 2750) 0.5/1.0 ≤0.5–>32 99.6 (2739) 0.4 (11)
2014 (N = 2000) 0.5/2.0 ≤0.5–4.0 99.5 (1990) 0.5 (10)
All years (9786) 1/2 ≤0.5–>32 99.1 (9701) 0.9 (85)
Total (33,765) 0.5/1 ≤0.5–>32 96.0 (32,419) 4.0 (1346)
a MIC range of total strains tested in the laboratory between 2010 and 2014.
b Colistin susceptibility category according to break points of CLSI8 for Acinetobacter spp. and Pseudomonas spp., and EUCAST9 for Enterobacteri-
aceae members.
Table 2 – Number of colistin-resistant Enterobacteriaceae family members isolated between 2010 and 2014, in HC-FMUSP.
Isolates/year Number of colistin-resistant Enterobacteriaceae isolates (%)a
2010 2011 2012 2013 2014 Total
K. pneumoniae 82 (73.9) 136 (84.5) 120 (76.0) 290 (83.8) 347 (90.6) 975 (84.1)
E. cloacae 4 (3.6) 6 (3.7) 27 (17.1) 30 (8.7) 19 (5.0) 86 (7.4)
E. aerogenes 21 (18.9) 10 (6.2) 4 (2.5) 3 (0.9) 4 (1.0) 42 (3.6)
E. coli 2 (1.8) 5 (3.1) 4 (2.5) 13 (3.8) 12 (3.1) 36 (3.1)
C. freundii 0 (0.0) 2 (1.2) 1 (0.6) 3 (0.9) 0 (0.0) 6 (0.5)
Salmonella spp. 2 (1.8) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 5 (0.4)
Pantoea spp. 0 (0.0) 2 (1.2) 0 (0.0) 1 (0.3) 1 (0.3) 4 (0.3)
K. ornithinolytica 0  (0.0) 0 (0.0) 0 (0.0) 3 (0.9) 0 (0.0) 3 (0.2)
E. asburie 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.6) 0 (0.0) 2 (0.1)
Total 111 (100) 161 (100) 158 (100) 346 (100) 383 (100) 1159 (100)
a T, 201 9
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In conclusion, in our institution colistin resistance is
ncreasing among K. pneumoniae isolates, posing a real prob-
em for treating these infections. Fortunately, this trend has
ot been observed among non-fermentative isolates that still
emain highly susceptible to colistin. The increase of resis-
ance to colistin, observed in this study, is a global realityPlease cite this article in press as: Rossi F, et al. Emergence of colistin resis
over ﬁve years. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016.
nd measures should be undertaken to prevent the complete
oss of activity of this drug and dissemination of multi-drug
esistant bacteria.6.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.BJID 657 1–4
tance in the largest university hospital complex of São Paulo, Brazil,
09.011
Acknowledgments
We  would like to thank Rosilaine Souza Arruda Teberges by
assistance on the WHONET data analysis. We also thank the
164
165
ARTICLE IN PRESSBJID 657 1–4
 . 2 0 1
r
1
1
1
1
1
1
1
1
1
1
20. Girardello R, Bispo PJ, Yamanaka TM, Gales AC. Cation
concentration variability of four distinct Mueller-Hinton agar
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
2524  b r a z j i n f e c t d i s
Microbiology Laboratory group of HC-FMUSP for the great con-
tribution to clinical routine.
 e  f  e  r  e  n  c  e  s
1. Brazilian Health Surveillance Agency (ANVISA). Boletim
Informativo: Seguranc¸a e qualidade em servic¸o de saúde n◦ 9:
Relatório da resistência microbiana em infecc¸ões primárias
de corrente sanguínea conﬁrmadas laboratorialmente
relacionadas ao uso de cateter venoso central em unidades
de terapia intensiva. Available from:
http://portal.anvisa.gov.br/wps/content/Anvisa+Portal/Anvisa/
Inicio/Servicos+de+Saude/Assunto+de+Interesse/Boletim+
Seguranca+do+Paciente/Seguranca+e+qualidade+em+servico+
de+saude+n+9; 2013 [accessed 03.01.15].
2.  Yau W,  Owen RJ, Poudyal A, et al. Colistin hetero-resistance in
multidrug-resistant Acinetobacter baumannii clinical isolates
from the Western Paciﬁc region in the SENTRY antimicrobial
surveillance programme. J Infect. 2009;58:138–44.
3.  Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial
resistance among Gram-negative bacilli isolated from Latin
America: results from SENTRY Antimicrobial Surveillance
Program (Latin America, 2008–2010). Diagn Microbiol Infect
Dis. 2012;73:354–60.
4. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial
susceptibility of Gram-negative organisms isolated from
patients hospitalized in intensive care units in United States
and European hospitals (2009–2011). Diagn Microbiol Infect
Dis. 2014;78:443–8.
5. Dias VC, Diniz CG, Peter AC, et al. Epidemiological
characteristics and antimicrobial susceptibility among
carbapenem-resistant non-fermenting bacteria in Brazil. J
Infect Dev Ctries. 2016;10:544–53.
6. Abboud CS, Monteiro J, Stryjewski ME, et al. Post-surgical
mediastinitis due to carbapenem-resistant Enterobacteriaceae:
clinical, epidemiological and survival characteristics. Int J
Antimicrob Agents. 2016;47:386–90.
7. CLSI, Clinical Laboratory Standard Institute. Methods for
Dilution Antimicrobial Susceptibility Tests for Bacteria That
Grow Aerobically; Approved Standard. Ninth ed; 2012.
Document M07-A9. Wayne, PA.Please cite this article in press as: Rossi F, et al. Emergence of colistin resis
over ﬁve years. Braz J Infect Dis. 2016. http://dx.doi.org/10.1016/j.bjid.2016
8. CLSI, Clinical Laboratory Standard Institute. Performance
Standards for Antimicrobial Susceptibility Testing;
Twenty-Six Informational Supplement. Document M100-S26,
Wayne, PA; 2016. 6;x x x(x x):xxx–xxx
9. European Committee on Antimicrobial Susceptibility Testing.
Breakpoint interpretation of MICs and zone diameters,
Version 4.0; 2016.
0. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance
in  Acinetobacter and its association with previous colistin
therapy. Antimicrob Agents Chemother. 2008;52:351–2.
1. Giani T, Arena F, Vaggelli G, et al. Large nosocomial outbreak
of  colistin-resistant, carbapenemase-producing Klebsiella
pneumoniae traced to clonal expansion of an mgrB deletion
mutant. J Clin Microbiol. 2015;53:3341–4.
2. Gales AC, Jones RN, Sader HS. Contemporary activity of
colistin and polymyxin B against a worldwide collection of
Gram-negative pathogens: results from the SENTRY
Antimicrobial Surveillance Program (2006–09). J Antimicrob
Chemother. 2011;66:2070–4.
3. Monteiro J, Santos AF, Asensi MD, Peirano G, Gales AC. First
report of KPC-2-producing Klebsiella pneumoniae strains in
Brazil. Antimicrob Agents Chemother. 2009;53:333–4.
4.  Zavascki AP, Machado AB, de Oliveira KR, et al.
KPC-2-producing Enterobactercloacae in two cities from
Southern Brazil. Int J Antimicrob Agents. 2009;34:286–8.
5. Jácome PR, Alves LR, Cabral AB, Lopes AC, Maciel MA.  First
report of KPC-producing Pseudomonas aeruginosa in Brazil.
Antimicrob Agents Chemother. 2012;56:4990.
6. Rizek C, Fu L, Dos Santos LC, et al. Characterization of
carbapenem-resistant Pseudomonas aeruginosa clinical
isolates, carrying multiple genes coding for this antibiotic
resistance. Ann Clin Microbiol Antimicrob. 2014;13:43.
7.  Provasi Cardoso J, Cayô R, Girardello R, Gales AC. Diversity of
mechanisms conferring resistance to -lactams among
OXA-23-producing Acinetobacter baumannii clones. Diagn
Microbiol Infect Dis. 2016;85:90–7.
8. Santana Rde C, Gaspar GG, Vilar FC, Bellissimo-Rodrigues F,
Martinez R. Secular trends in Klebsiella pneumoniae isolated in
a  tertiary-care hospital: increasing prevalence and
accelerated decline in antimicrobial susceptibility. Rev Soc
Bras Med Trop. 2016;49:177–82.
9. Olaitan AO, Morand S, Rolain JM. Emergence of
colistin-resistant bacteria in humans without colistin usage:
a  new worry and cause for vigilance. Int J Antimicrob Agents.
2016;47:1–3.BJID 657 1–4
tance in the largest university hospital complex of São Paulo, Brazil,
.09.011
brands inﬂuences polymyxin B susceptibility results. J Clin
Microbiol. 2012;50:2414–8.
253
254
